

## 해외 바이오의약품 임상 현황 (2019.08.20~2019.08.26)

한국바이오의약품협회, 2019.8.27  
출처: ClinicalTrials.gov

### ○ 미국 5건

| NCT Number  | Title   | Conditions                                 | Interventions   | Sponsor/Collaborators   | Phases  |
|-------------|---|--|---|---|---------|
| NCT04019444 | Dose-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects                                       | Rabies Rabies Immunisation                 | Biological: ChAd155-RG Other: Placebo Biological: Rabies Vaccine  | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| NCT03943901 | Split-Dose R-CHOP for Older Adults With DLBCL   | Diffuse Large B Cell Lymphoma DLBCL Cancer | Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim | University of Wisconsin, Madison Medical College of Wisconsin | Phase 2 |
| NCT03713684 | Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) | Type 2 Diabetes Mellitus                   | Drug: Efpeglenatide SAR439977 Drug: Placebo Drug: Insulin glargine  | Sanofi  | Phase 3 |
| NCT03934541 | Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants   | HIV Infections                             | Biological: MPER-656 Liposome Vaccine Biological: Placebo for MPER-656 Liposome Vaccine                               | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| NCT04053634 | Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations  | Chronic Obstructive Pulmonary Disease      | Biological: Benralizumab Biological: Placebo  | AstraZeneca   | Phase 3 |

### ○ 영국 2건

| NCT Number  | Title  | Conditions                            | Interventions                                | Sponsor/Collaborators | Phases  |
|-------------|--|---------------------------------------|--|-----------------------|---------|
| NCT03998683 | A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis   | Psoriasis                             | Drug: Guselkumab 100 mg Drug: Placebo        | Janssen-Cilag Ltd.    | Phase 3 |
| NCT04053634 | Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations | Chronic Obstructive Pulmonary Disease | Biological: Benralizumab Biological: Placebo | AstraZeneca           | Phase 3 |

### ○ 프랑스 1건

| NCT Number  | Title  | Conditions | Interventions                         | Sponsor/Collaborators | Phases  |
|-------------|--|------------|---------------------------------------|-----------------------|---------|
| NCT03998683 | A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis | Psoriasis  | Drug: Guselkumab 100 mg Drug: Placebo | Janssen-Cilag Ltd.    | Phase 3 |

### ○ 독일 1건

| NCT Number  | Title  | Conditions | Interventions                         | Sponsor/Collaborators | Phases  |
|-------------|--|------------|---------------------------------------|-----------------------|---------|
| NCT03998683 | A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis | Psoriasis  | Drug: Guselkumab 100 mg Drug: Placebo | Janssen-Cilag Ltd.    | Phase 3 |

### ○ 중국 6건

| NCT Number  | Title  | Conditions   | Interventions   | Sponsor/Collaborators   | Phases          |
|-------------|--|--|---|---|-----------------|
| NCT04058470 | Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma  | Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Follicular Lymphoma Grade IIIb Transformed Lymphoma EBV-Positive DLBCL, Nos ALK-Positive Anaplastic Large Cell Lymphoma | Drug: Toripalimab Drug: R-CHOP Protocol   | Huiqiang Huang Sun Yat-sen University   | Phase 1 Phase 2 |
| NCT04066790 | Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer   | Breast Cancer  | Drug: Pyrotinib Drug: nab-Paclitaxel Drug: Trastuzumab Drug: EC chemotherapy Procedure: Surgery | Shanghai Jiao Tong University School of Medicine Jiangsu HengRui Medicine Co., Ltd. | Phase 2         |
| NCT04065672 | Low-dose IL-2 Treatment on Behcet's Disease  | Behcet's Disease   | Drug: Low-dose IL-2   | Peking University People's Hospital   | Phase 2         |
| NCT04063358 | Anti-VEGF Intravitreal Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery   | Diabetic Macular Edema Cataract  | Drug: Lucentis  | Second Military Medical University  | Phase 3         |
| NCT04063163 | A Randomized, Double-blind, Placebo-controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Extensive Stage Small Cell Lung Cancer   | Drug: HLX10 Drug: carboplatin and etoposide Drug: placebo                                       | Shanghai Henlius Biotech  | Phase 3         |
| NCT04060888 | A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus  | Lupus Erythematosus, Systemic  | Drug: Ustekinumab (approximately 6 mg/kg) Drug: Ustekinumab 90 milligram (mg) Drug: Placebo     | Janssen Research & Development, LLC   | Phase 3         |